Skip to main content
Premium Trial:

Request an Annual Quote

Optivia Inks Drug-Interaction Collaboration with FDA

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Optivia Biotechnology today said that it will collaborate with the US Food and Drug Administration on identifying potentially harmful drug-dietary supplement interactions.

Under the collaboration, seven key drug transporters associated with drug-drug interactions will be examined using Optivia's in vitro transporter technology platform, which uses polarized mammalian cell assays that closely model human biology. The collaboration will assess the ability of certain dietary supplements, such as black cohosh, green tea, ginko biloba, kava, usnic acid,0 and others, to affect various drug transporters.

The goal of the collaboration is to identify potentially harmful drug-dietary supplement interactions, such as the interaction of acetaminophen and other drugs associated with liver toxicity, said Menlo Park, Calif.-based Optivia.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.